Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hengmiao Cheng

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
ACS Medicinal Chemistry Letters|September 28, 2018
Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung CancerHengmiao Cheng, Simon Planken
Bioorganic & Medicinal Chemistry Letters|March 13, 2016
Recent progress on third generation covalent EGFR inhibitorsHengmiao Cheng, Sajiv K Nair, Brion W Murray
Current Cancer Drug Targets|January 10, 2013
Targeting the mTOR pathway in tumor malignancyHengmiao Cheng, Marlena Walls, Sangita M Baxi, et al.
Toxicology and Applied Pharmacology|June 15, 2023
The pharmacologic and toxicologic characterization of the potent and selective KRAS G12D inhibitors ERAS-4693 and ERAS-5024Alexei Brooun, Jingchuan Zhang, Chingyuan Li, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|May 22, 2009
In vivo evaluation of 11beta-hydroxysteroid dehydrogenase activity in the rabbit eyeScott Anderson, Samantha Carreiro, Terri Quenzer, et al.
Bioorganic & Medicinal Chemistry Letters|March 15, 2006
Discovery of potent and orally active MTP inhibitors as potential anti-obesity agentsJin Li, Peter Bertinato, Hengmiao Cheng, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2013
Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone seriesHengmiao Cheng, Jacqui E Hoffman, Phuong T Le, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2011
Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitorsKevin K C Liu, Xiaojun Huang, Shubha Bagrodia, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTORPhuong T Le, Hengmiao Cheng, Sacha Ninkovic, et al.
Bioorganic & Medicinal Chemistry Letters|January 10, 2008
Comparative structure-activity relationship studies of 1-(5-methylsulfonylpyrid-2-yl)-5-alkyl and (hetero)aryl triazoles and pyrazoles in canine COX inhibitionSubas M Sakya, Andrei Shavnya, Hengmiao Cheng, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
ACS Medicinal Chemistry Letters|September 28, 2018
Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung CancerHengmiao Cheng, Simon Planken
Bioorganic & Medicinal Chemistry Letters|March 13, 2016
Recent progress on third generation covalent EGFR inhibitorsHengmiao Cheng, Sajiv K Nair, Brion W Murray
Current Cancer Drug Targets|January 10, 2013
Targeting the mTOR pathway in tumor malignancyHengmiao Cheng, Marlena Walls, Sangita M Baxi, et al.
Toxicology and Applied Pharmacology|June 15, 2023
The pharmacologic and toxicologic characterization of the potent and selective KRAS G12D inhibitors ERAS-4693 and ERAS-5024Alexei Brooun, Jingchuan Zhang, Chingyuan Li, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|May 22, 2009
In vivo evaluation of 11beta-hydroxysteroid dehydrogenase activity in the rabbit eyeScott Anderson, Samantha Carreiro, Terri Quenzer, et al.
Bioorganic & Medicinal Chemistry Letters|March 15, 2006
Discovery of potent and orally active MTP inhibitors as potential anti-obesity agentsJin Li, Peter Bertinato, Hengmiao Cheng, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2013
Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone seriesHengmiao Cheng, Jacqui E Hoffman, Phuong T Le, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2011
Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitorsKevin K C Liu, Xiaojun Huang, Shubha Bagrodia, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTORPhuong T Le, Hengmiao Cheng, Sacha Ninkovic, et al.
Bioorganic & Medicinal Chemistry Letters|January 10, 2008
Comparative structure-activity relationship studies of 1-(5-methylsulfonylpyrid-2-yl)-5-alkyl and (hetero)aryl triazoles and pyrazoles in canine COX inhibitionSubas M Sakya, Andrei Shavnya, Hengmiao Cheng, et al.
Pageof 3